Posted by Michael Wonder on 15 Jun 2023
Amylyx Pharmaceuticals completes negotiation process and signs letter of intent with the pCPA for Albrioza for the treatment of ALS
15 June 2023 - Amylyx will now work with federal, provincial, and territorial drug plans to ensure public coverage is available to eligible Canadians with amyotrophic lateral sclerosis.
Amylyx Pharmaceuticals today announced that it has completed the negotiation process and entered into a letter of intent with the pan-Canadian Pharmaceutical Alliance for the terms and conditions under which Albrioza (sodium phenylbutyrate and ursodoxicoltaurine) would qualify for reimbursement through federal, provincial, and territorial public drug plans for the treatment of amyotrophic lateral sclerosis.
